ARK Fintech Innovation ETF vs Inovio Pharmaceuticals Inc — how do they compare? ARK Fintech Innovation ETF trades at $42.79, while Inovio Pharmaceuticals Inc trades at $0.78 (market cap $78.55M). The key difference: ARK Fintech Innovation ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKF | INO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $2.87 |
52-Week Low | $36.14 | $0.66 |
Market Cap | — | $78.55M |
Enterprise Value | — | $49.56M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Trailing returns across standard periods
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →